Light therapy could spare kidneys in rare cancer trial
Disease control
Completed
This study tests a drug called TOOKAD (padeliporfin) that is activated by light to destroy low-grade tumors in the kidney or ureter. About 100 adults with this rare cancer will receive the treatment in two phases, with follow-up for up to 4 years. The goal is to see if the therap…
Phase: PHASE3 • Sponsor: Steba Biotech S.A. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC